Abbott ABT today announced the availability of a new molecular test in
the European Union and New Zealand designed to identify the presence of gene
rearrangements associated with a specific form of non-small-cell lung cancer. These rearrangements in a gene known as ALK have been implicated in the formation of cancerous tumors in patients
with NSCLC.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in